BIIB March 27th Options Begin Trading

Biogen (BIIB) is trading at $186.62 and the article lays out two option strategies: selling-to-open the $185 put (bid $7.10) which implies a $177.90 effective cost basis, is ~1% OTM, has a 56% chance to expire worthless and would yield 3.84% (28.04% annualized) if it does. The covered-call trade selling the $190 call (bid $6.60) is ~2% OTM with a 52% chance to expire worthless, would produce a 5.35% total return if called (3.54% boost, 25.84% annualized if not), and implied volatilities are 36% (put) and 35% (call) versus a 12‑month trailing volatility of 33%.

Analysis

Market structure: Short-dated option sellers and cash-rich income strategies are the clear beneficiaries—selling the Mar27 BIIB 185 put (collect $7.10) or the 190 covered call (collect $6.60) generates a 3.8–5.4% payoff over ~6 weeks (28% and 25.8% annualized). Market makers and flow desks capture bid/offer friction; downside losers are leveraged directional longs in BIIB if a clinical/regulatory shock >10–30% occurs before expiry. The modest IV premium (35–36% vs realized 33%) signals supply of protection is only slightly tight, consistent with demand for short-dated yield rather than panic hedging.

Risk assessment: Tail risk is dominated by binary biotech outcomes—FDA/phase readouts can move BIIB +/-30–70% in days; implied odds (~52–56% OTM) understate jump risk because Greeks ignore fat tails. Immediate horizon (days–weeks) is dominated by gamma and pinning into Mar27 expiry; short-term (weeks–months) by upcoming earnings/clinical windows; long-term (quarters–years) by product pipeline and patent/M&A dynamics. Hidden dependencies include dealer hedging flows that can exacerbate moves if sellers are forced to unwind and IV expansion that can widen bid/ask and destroy option trade economics.

Trade implications: For yield-biased allocation, prefer cash-secured short put or covered-call overlays sized 1–3% of portfolio with hard stops and defined-risk spreads to cap downside; avoid naked short puts >3% exposure given binary risk. Relative-value: long BIIB vs short IBB (biotech ETF) or vs XLV can isolate idiosyncratic upside while hedging sector moves; prefer put-spread (185/175) to monetize premium while capping tail loss. Use options: sell premium when IV > realized +5–8 vol pts; buy protection (buy 170–165 puts) if IV rises and you are long.

Contrarian angles: Consensus frames these trades as “income” but underprices event risk—options sellers may be picking up 3–5% for taking on >20% binary risk within weeks, an asymmetry that can be exploited with defined-risk structures. Reaction is likely underdone: a small adverse readout would vaporize short-tail income and spike IV well above 60%, making naked short strategies costly to defend. Historical parallels: prior Biogen FDA/clinical shocks show >40% intraday gaps; use that as a calibration—avoid naked exposure >2% until a 30–60 day quiet period after major catalysts.

Key Decisions for Investors

• Sell cash‑secured BIIB Mar27 185 puts (collect $7.10) sized 1–2% of portfolio to establish a synthetic buy at $177.90; buy back if BIIB trades <170 pre‑expiry or IV rises >+10 vol points (risk control).
• Buy BIIB up to a 2–3% position and sell Mar27 190 covered calls (collect $6.60) to target 5.35% gross return to expiry; roll out/adjust if stock >195 or IV >45% prior to expiry.
• If unwilling to take assignment, sell BIIB 185/175 put spreads Mar27 sized 1–2% to cap downside to 10 points while collecting net premium (~$X, adjust size so max loss ≤2% portfolio).
• Implement relative-value trade: long BIIB (1–2%) vs short IBB (1%) to isolate idiosyncratic moves ahead of clinical/earnings windows; unwind if sector dispersion falls below 5% or BIIB moves >+20% intraday.
• For protection on existing BIIB holdings >3% portfolio, buy Mar27 170 puts (or 165–170 put spread) when IV ≤45%; if IV >60% avoid buying protection and instead trim exposure by 25%.